Hematologic (blood) cancers / bone marrow conditioning and CD66 program

The indications for bone marrow transplantation are increasing from hematological malignancies to more recently solid tumours and numerous autoimmune conditions. Traditional conditioning regimens are associated with morbidity and mortality from chemotherapy, limiting their use particularly in pediatric and rare diseases.

Conditions like systemic amyloid light chain amyloidosis (SALA), an orphan disease that is often treated by autologous transplant, could benefit from more tolerable conditioning regimens. Novel cell and gene therapies could also increase their utilisation by minimising chemotherapy conditioning approaches.

Telix’s rare disease portfolio targets cluster of differentiation 66 (CD66), a receptor expressed on specific types of immune/blood cells and a potential target for novel conditioning radiopharmaceuticals.

Bone marrow conditioning & SALA worldwide

12 per million

annual incidence of SALA (systemic amyloid light chain amyloidosis), an orphan disease indication

11 months

median overall survival for SALA from diagnosis

30

countries where TLX66-CDx is currently approved and marketed as Scintimun®